Stockreport

Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF The consensus estimate for Q3 2024 revenue is $29.84 million, and the earnings are expected to come in at -$0.37 per share. The full year 2024's revenue is expected to b [Read more]